Search results for "double"

showing 10 items of 2879 documents

Efficacy and pharmacological appropriateness of cinnarizine and dimenhydrinate in the treatment of vertigo and related symptoms

2021

Vertigo is not itself a disease, but rather a symptom of various syndromes and disorders that jeopardize balance function, which is essential for daily activities. It is an abnormal sensation of motion that usually occurs in the absence of motion, or when a motion is sensed inaccurately. Due to the complexity of the etiopathogenesis of vertigo, many pharmacological treatments have been tested for efficacy on vertigo. Among these drugs, cinnarizine, usually given together with dimenhydrinate, appears to be the first-line pharmacotherapy for the management of vertigo and inner ear disorders. Based on these considerations, the present non-interventional study aimed to investigate the clinical …

AdultMalepharmacological treatment of vertigomedicine.medical_specialtyCinnarizineHealth Toxicology and MutagenesisDiseasedimenhydrinateArticleCinnarizine Dimenhydrinate Dizziness Pharmacological treatment of vertigo Vertigo Adult Double-Blind Method Drug Combinations Female Histamine H1 Antagonists Humans Male Middle Aged Cinnarizine Dimenhydrinatevertigo03 medical and health sciences0302 clinical medicinePharmacotherapyDouble-Blind MethodVertigoInternal medicinemedicineotorhinolaryngologic diseasesHumans030212 general & internal medicinecinnarizine030223 otorhinolaryngologydizzinessBalance (ability)biologybusiness.industryPublic Health Environmental and Occupational HealthRMiddle Agedbiology.organism_classificationDimenhydrinateDrug CombinationsTolerabilityConcomitantHistamine H1 AntagonistsMedicineFemalebusinessmedicine.drug
researchProduct

Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a1

2019

Background: There have been few studies conducted on the efficacy and safety of specific immunotherapy with allergen extracts of fungi compared with other allergen extracts, and there are no data on the major allergen Alt a 1 of the fungus Alternaria alternata. Objectives: We sought to evaluate the efficacy and safety of subcutaneous immunotherapy with 2 different doses of Alt a 1 in patients with rhinoconjunctivitis caused by sensitization to A alternata. Method: We performed a multicenter, randomized, double-blind, placebo-controlled trial with Alt a 1 administered subcutaneously in patients with allergic rhinoconjunctivitis with or without controlled asthma aged 12 to 65 years. Three gro…

AdultMalesafetyAllergymedicine.medical_specialtyAllergen immunotherapyAl·lèrgiaAdolescentImmunologyefficacyPlacebo-controlled studyPlacebomedicine.disease_causeFungal ProteinsYoung AdultAllergenDouble-Blind Methodchildrensubcutaneous immunotherapyInternal medicinemedicineadultsImmunology and AllergyHumansmolecular immunotherapyAdverse effectChildAgedConjunctivitis AllergicAllergen immunotherapyIntention-to-treat analysisbusiness.industryrhinoconjunctivitisclinical trialAllergensImmunoglobulin EMiddle Agedmedicine.diseaseAsthmaClinical trialfungal allergyDesensitization ImmunologicImmunoglobulin GAlt a 1Femalebusinesspurified allergen
researchProduct

Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels.

2012

N 1 -methylnicotinamide (MNA + ) has until recently been thought to be a biologically inactive product of nicotinamide metabolism in the pyridine nucleotides pathway. However, the latest observations imply that MNA + may exert antithrombotic and anti-inflammatory effects through direct action on the endothelium. We examined both in vivo and in vitro whether the compound might induce vasorelaxation in human blood vessels through the improvement of nitric oxide (NO) bioavailability and a reduction of oxidative stress mediated by endothelial NO synthase (eNOS) function. MNA + treatment (100 mg/m 2 orally) in healthy normocholesterolemic and hypercholesterolemic subjects increased the l-argini…

AdultNiacinamidemedicine.medical_specialtyEndotheliumBrachial ArteryNitric Oxide Synthase Type IIIHypercholesterolemiachemistry.chemical_elementCalciumIn Vitro Techniquesmedicine.disease_causeNitric OxideNitric oxidechemistry.chemical_compoundN^{1}-methylnicotinamideDouble-Blind MethodEnosnitric oxideInternal medicineInternal MedicinemedicineHumansflow-mediated dilationCalcimycinCells Culturedendothelial nitric oxide synthaseoxidized low-density lipoproteinbiologyDose-Response Relationship DrugChemistrySuperoxidebiology.organism_classificationendothelial cellsAcetylcholineOxygenVasodilationOxidative Stressmedicine.anatomical_structureEndocrinologysuperoxideEndothelium VascularAcetylcholineOxidative stressmedicine.drugLipoproteinHypertension (Dallas, Tex. : 1979)
researchProduct

Consistencies and discrepancies in self- and observer-rated anxiety scales. A comparison between the self- and observer-rated Marks-Sheehan scales.

1990

The Marks-Sheehan anxiety scales are the only scales where self-ratings and observer ratings are perfectly matched by the number, the content and the scaling of the items. Therefore these scales are an excellent tool to investigate the compatibility and to study different structures in self- and observer ratings. This was done by using the data material on the Marks-Sheehan scales of the Cross National Collaborative Panic Study. In this study 1168 outpatients who met the DSM-III criteria for panic disorder were randomly allocated either to alprazolam, imipramine or placebo treatment. Our results show that the Marks-Sheehan scales are highly comparable to other established rating scales. Bot…

AdultPersonality TestsImipraminePersonality Assessmentbehavioral disciplines and activitiesDouble-Blind MethodRating scalemedicineHumansPharmacology (medical)Biological PsychiatryAlprazolamGeneral NeurosciencePanic disorderSelfBehaviorally anchored rating scalesPanicGeneral MedicineMiddle Agedmedicine.diseaseAnxiety DisordersPanicObserver ratingPsychiatry and Mental healthNeuropsychology and Physiological PsychologyAlprazolamAnxietymedicine.symptomPsychologySocial psychologymedicine.drugClinical psychologyEuropean archives of psychiatry and clinical neuroscience
researchProduct

Self- and observer assessment in anxiolytic drug trials: A comparison of their validity

1990

Self-rating scales are considered to be less useful for comparing different treatments in anxiety patients than observer-rating scales. However, the empirical evidence for this assumption is not adequate. A self-rating inventory of 35 items related to anxiety was perfectly parallel with an observer-rating inventory. Both instruments were used in the Cross National Collaborative Panic Study to compare the efficacy of imipramine, alprazolam and placebo in an 8-week drug trial in a sample of 1168 outpatients. The variance of the self-rating assessments was about two times higher. Both scales were equally sensitive to change; however, the measurement of change by means of the self-rating scale …

AdultPersonality TestsImipraminemedicine.medical_specialtyPsychometricsPsychometricsmedicine.drug_classPersonality AssessmentAnxiolyticDouble-Blind MethodRating scalemedicineHumansPharmacology (medical)PsychiatryBiological PsychiatryAlprazolamGeneral NeurosciencePanic disorderReproducibility of ResultsPanicGeneral MedicineMiddle Agedmedicine.diseaseAnxiety DisordersPanicPsychiatry and Mental healthNeuropsychology and Physiological PsychologyAlprazolamAnxietymedicine.symptomPersonality Assessment InventoryPsychologyClinical psychologymedicine.drugEuropean Archives of Psychiatry and Clinical Neuroscience
researchProduct

SQ HDM SLIT-tablet (ALK) in treatment of asthma – Post hoc results from a randomised trial

2014

SummaryIntroductionIn a double-blind, placebo-controlled trial (EudraCT identifier: 2006-001795-20), the standardised quality (SQ) house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (ALK, Denmark) was investigated.MethodThe trial included 604 subjects, ≥14 years, with mild-moderate HDM allergic asthma. Subjects were randomised 1:1:1:1 to 1, 3 or 6 SQ-HDM or placebo once daily. The primary endpoint was reduction in inhaled corticosteroid (ICS) after one year. ICS reduction, asthma quality of life questionnaire (AQLQ) and asthma control questionnaire (ACQ) score was analysed post hoc in a subgroup with daily ICS use of 400–800 μg and ACQ score of 1–1.5, corresponding to partly contr…

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtymedicine.drug_classPopulationPlaceboHouse dust miteDouble-Blind MethodQuality of lifeSurveys and QuestionnairesmedicineClinical endpointAnimalsHumansSLIT-tabletBudesonideeducationGlucocorticoidsICS reductionAsthmaHouse dust miteSublingual Immunotherapyeducation.field_of_studybiologybusiness.industryPyroglyphidaemedicine.diseasebiology.organism_classificationAsthma; Asthma quality of life; House dust mite; ICS reduction; SLIT-tabletAsthmaTreatment OutcomeAsthma Control QuestionnaireQuality of LifeCorticosteroidAsthma quality of lifebusinessTabletsRespiratory Medicine
researchProduct

Omalizumab (Xolair®) improves quality of life in adult patients with allergic asthma: a review

2003

Abstract Physicians are increasingly aware that asthma causes significant impairment of the patient's physical, psychological, and social well-being. Whilst standard clinical endpoints provide significant information on airway status during treatment, it is important to determine whether such improvements overcome the functional impairment that patients have to deal with on a daily basis. As such, assessment of health-related quality of life (QoL) is an important aspect of asthma management in clinical practice. Omalizumab (Xolair ® ) is a recombinant humanized monoclonal anti-immunoglobulin E (IgE) antibody that represents a new therapeutic approach to IgE-mediated diseases such as allergi…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin EPlaceboTherapeutic approachDouble-Blind MethodQuality of lifeInternal medicinemedicineClinical endpointHumansAnti-Asthmatic Agentsanti-IgEChildquality of life.AgedAsthmabiologybusiness.industryRespiratory diseaseAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaAntibodies Anti-IdiotypicQuality of Lifebiology.proteinPhysical therapyomalizumabbusinessAttitude to Healthallergic asthmamedicine.drugRespiratory Medicine
researchProduct

Risk of low bone mineral density and low body mass index in patients with non-celiac wheat-sensitivity: a prospective observation study.

2014

Background Non-celiac gluten sensitivity (NCGS) or ‘wheat sensitivity’ (NCWS) is included in the spectrum of gluten-related disorders. No data are available on the prevalence of low bone mass density (BMD) in NCWS. Our study aims to evaluate the prevalence of low BMD in NCWS patients and search for correlations with other clinical characteristics. Methods This prospective observation study included 75 NCWS patients (63 women; median age 36 years) with irritable bowel syndrome (IBS)-like symptoms, 65 IBS and 50 celiac controls. Patients were recruited at two Internal Medicine Departments. Elimination diet and double-blind placebo controlled (DBPC) wheat challenge proved the NCWS diagnosis. A…

AdultRiskmedicine.medical_specialtySettore MED/09 - Medicina InternaBone densityGlutensNon-celiac wheat sensitivityOsteoporosisGastroenterologyBody Mass IndexIrritable Bowel SyndromeYoung AdultDouble-Blind MethodBone DensityInternal medicineElimination dietmedicinePrevalenceHumansMultiple food allergyProspective StudiesProspective cohort studyIrritable bowel syndromeBone mineralMedicine(all)business.industryGeneral MedicineMiddle Agedmedicine.diseaseOsteopeniaBone Diseases MetabolicCeliac DiseaseIntestinal DiseasesEndocrinologyOsteoporosisnon-celiac wheat-sensitivityFemalebone mineral density; body mass index; non-celiac wheat-sensitivitybusinessbone mineral densityBody mass indexResearch ArticleBMC medicine
researchProduct

Double Negative (CD19+IgG+IgD-CD27-) B Lymphocytes: A New Insight from Telomerase in Healthy Elderly, in Centenarian Offspring, and in Alzheimer’s Di…

2014

Background: We have previously reported the increase of IgD-CD27- (Double Negative, DN) B cell population in the aged. These memory B cells have short telomeres and poor abilities to proliferate in vitro. Here, we investigated whether the low ability of DN B cells to proliferate depends on the expression levels of the CD307d and CD22 inhibitory receptors or whether DN B cells can proliferate and reactivate telomerase by the engagement of both innate and adaptive immune receptors. Methods: Phenotypic analyses were made by using flow cytometry. Quantitative analysis of telomerase activity was made by using a TRAP and a photometric enzyme immunoassay in young, healthy elderly, centenarian offs…

AdultTelomeraseAgingImmunologyPopulationNaive B cellB-Lymphocyte SubsetsReceptors Antigen B-CellCentenarian offspringLymphocyte ActivationSeverity of Illness IndexCD19ImmunophenotypingYoung AdultAlzheimer DiseasemedicineIgD-CD27- (Double Negative DN) B cell population in the aged DN B cell telomerase activity in young elderly CO and AD patientsImmunology and AllergySettore MED/05 - Patologia ClinicaHumanseducationTelomeraseB cellCellular SenescenceAgedInflammationSettore MED/04 - Patologia GeneraleAged 80 and overeducation.field_of_studyCD40biologyB lymphocyteAge FactorsTLR9ImmunosenescenceMiddle Agedmedicine.anatomical_structurePhenotypeImmunologyAntigens Surfacebiology.proteinAlzheimerAging; Telomerase; B lymphocytes; Alzheimer; Centenarian offspring; InflammationSettore MED/26 - NeurologiaImmunologic Memory
researchProduct

Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, …

2012

The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were…

AdultTime FactorsOriginalMigraine DisordersPopulationAlmotriptanClinical NeurologyCarbazolesSubgroup analysisSeverity of Illness IndexAdult; Carbazoles; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Female; Humans; Italy; Menstruation Disturbances; Middle Aged; Migraine Disorders; Proportional Hazards Models; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors; Treatment Outcome; TryptaminesDisability EvaluationDouble-Blind MethodAlmotriptanSeverity of illnessMedicineHumanseducationMigraine Menstrually related migraine Frovatriptan AlmotriptanMenstrually related migraineMenstruation DisturbancesMigraineMenstrually related migraineProportional Hazards Modelseducation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTryptaminesSerotonin Receptor Agonistsfrovatriptan; migraine; menstrually related migraine; almotriptanAnesthesiology and Pain MedicineTreatment OutcomeMigraineItalyAnesthesiaFemaleNeurology (clinical)businessFrovatriptanFrovatriptanmedicine.drug
researchProduct